Scholarlink

Background <p>This study evaluates the changing burden of hepatitis C (HCV) among women of reproductive age (15–49&#xa0;years) in China from 1990–2021 and forecasts trends to 2035.</p> Methods <p>Using data from the Global Burden of Disease 2021 study, we analyzed age-standardized rates (ASRs) for incidence, prevalence, mortality, and disability-adjusted life years (DALYs) related to acute and chronic HCV in this population. Statistical analyses included estimating annual percentage changes (EAPCs), applying Poisson-based age-period-cohort (APC) modeling to assess epidemiological drivers, and employing Bayesian APC modeling for future projections. Decomposition analysis was used to quantify contributions from population growth, aging, and epidemiological factors.</p> Results <p>From 1990 to 2021, all ASRs for HCV among women of reproductive age in China showed significant declines, with rates of decrease surpassing global averages. Despite this progress, China remained a high-burden country for this group in 2021, with a large reservoir of chronic HCV cases. A notable rebound in the incidence of chronic HCV occurred after 2010. Epidemiological trends displayed clear age stratification: the most substantial improvements were observed in younger cohorts (aged 15–24&#xa0;years), while older groups (aged 45–49&#xa0;years) experienced slower declines or recent rebounds in incidence. Decomposition analysis indicated that the reduction in disease burden was primarily driven by epidemiological improvements (e.g., in prevention and treatment), which successfully offset the adverse effects of population growth. This pattern contrasts with the global trend, where increasing burden is largely attributed to demographic factors. Projections suggest a continued decline in ASRs and case numbers through 2035, although the rate of decline is expected to slow.</p> Conclusions <p>Historical HCV control measures for women of reproductive age in China have been effective, as evidenced by steep declines in mortality and DALYs. However, persistent challenges include a substantial existing patient pool and a resurgent incidence, particularly among older individuals within this demographic. This study precisely quantifies a successful epidemiological transition and identifies a shift in risk profiles, underscoring the continued need for sustained, age-tailored public health interventions to achieve HCV elimination goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Ying Zhang,
  • Jing Yan,
  • Meng Li,
  • Chaoyan Yue

摘要

Background

This study evaluates the changing burden of hepatitis C (HCV) among women of reproductive age (15–49 years) in China from 1990–2021 and forecasts trends to 2035.

Methods

Using data from the Global Burden of Disease 2021 study, we analyzed age-standardized rates (ASRs) for incidence, prevalence, mortality, and disability-adjusted life years (DALYs) related to acute and chronic HCV in this population. Statistical analyses included estimating annual percentage changes (EAPCs), applying Poisson-based age-period-cohort (APC) modeling to assess epidemiological drivers, and employing Bayesian APC modeling for future projections. Decomposition analysis was used to quantify contributions from population growth, aging, and epidemiological factors.

Results

From 1990 to 2021, all ASRs for HCV among women of reproductive age in China showed significant declines, with rates of decrease surpassing global averages. Despite this progress, China remained a high-burden country for this group in 2021, with a large reservoir of chronic HCV cases. A notable rebound in the incidence of chronic HCV occurred after 2010. Epidemiological trends displayed clear age stratification: the most substantial improvements were observed in younger cohorts (aged 15–24 years), while older groups (aged 45–49 years) experienced slower declines or recent rebounds in incidence. Decomposition analysis indicated that the reduction in disease burden was primarily driven by epidemiological improvements (e.g., in prevention and treatment), which successfully offset the adverse effects of population growth. This pattern contrasts with the global trend, where increasing burden is largely attributed to demographic factors. Projections suggest a continued decline in ASRs and case numbers through 2035, although the rate of decline is expected to slow.

Conclusions

Historical HCV control measures for women of reproductive age in China have been effective, as evidenced by steep declines in mortality and DALYs. However, persistent challenges include a substantial existing patient pool and a resurgent incidence, particularly among older individuals within this demographic. This study precisely quantifies a successful epidemiological transition and identifies a shift in risk profiles, underscoring the continued need for sustained, age-tailored public health interventions to achieve HCV elimination goals.